SESN2 and hepatocellular carcinoma: A previous study found that the expression of SESN2 was positively associated with the IC50 of sorafenib in HCC cell lines and Sestrin 2 could induce sorafenib primary resistance by activation of the AKT and AMPK pathways (Dai et al., 2018).